Pramipexole versus sertraline in the treatment of depression in Parkinson's disease : A national multicenter parallel-group randomized study

In addition to treating the motor symptoms of Parkinson's disease, the dopamine agonist pramipexole has shown an antidepressant effect. The trials, however, included patients with motor complications, raising the question of whether the antidepressant benefit represented only a treatment-relate...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neurology 2006-05, Vol.253 (5), p.601-607
Main Authors: BARONE, Paolo, SCARZELLA, Leonardo, MARCONI, Roberto, ANTONINI, Angelo, MORGANTE, Letterio, BRACCO, Fulvio, ZAPPIA, Mario, MUSCH, Bruno
Format: Article
Language:English
Subjects:
Aged
Analysis of Variance
Antidepressive Agents - therapeutic use
Antiparkinson Agents - therapeutic use
Benzothiazoles - therapeutic use
Biological and medical sciences
Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases
Depressive Disorder, Major - complications
Depressive Disorder, Major - drug therapy
Female
Headache. Facial pains. Syncopes. Epilepsia. Intracranial hypertension. Brain oedema. Cerebral palsy
Humans
Male
Medical sciences
Middle Aged
Nervous system (semeiology, syndromes)
Neurology
Parkinson Disease - complications
Parkinson Disease - drug therapy
Psychiatric Status Rating Scales - statistics & numerical data
Sertraline - therapeutic use
Single-Blind Method
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In addition to treating the motor symptoms of Parkinson's disease, the dopamine agonist pramipexole has shown an antidepressant effect. The trials, however, included patients with motor complications, raising the question of whether the antidepressant benefit represented only a treatment-related motor improvement. To address this issue, we have conducted a 14-week randomized trial comparing pramipexole with an established antidepressant in patients without motor complications. At seven Italian centers, 67 Parkinsonian outpatients with major depression but no history of motor fluctuations and/or dyskinesia received open-label pramipexole (at 1.5 to 4.5 mg/day) or sertraline (at 50 mg/day). In both groups, the Hamilton Depression Rating Scale (HAM-D) score decreased throughout 12 weeks of treatment, but in the pramipexole group the proportion of patients who recovered, as defined by a final HAM-D score
ISSN:0340-5354
1432-1459
DOI:10.1007/s00415-006-0067-5